The ubiquitin ligases c-Cbl and Cbl-b play a crucial role in receptor downregulation by mediating multiple monoubiquitination of receptors and promoting their sorting for lysosomal degradation. Their function is modulated through interactions with regulatory proteins including CIN85 and PIX, which recognize a proline-arginine motif in Cbl and thus promote or inhibit receptor endocytosis. We report the structures of SH3 domains of CIN85 and b-PIX in complex with a proline-arginine peptide from Cbl-b. Both structures reveal a heterotrimeric complex containing two SH3 domains held together by a single peptide. Trimerization also occurs in solution and is facilitated by the pseudo-symmetrical peptide sequence. Moreover, ternary complexes of CIN85 and Cbl are formed in vivo and are important for the ability of Cbl to promote epidermal growth factor receptor (EGFR) downregulation. These results provide molecular explanations for a novel mechanism by which Cbl controls receptor downregulation.
Ligand binding to receptor tyrosine kinases (RTKs) causes receptor activation and initiates intracellular signaling cascades, which ultimately control biological responses such as cell proliferation, cellular adhesion or apoptosis 1 . To regulate the lifetime of this process, activated RTKs also trigger negative feedback loops that inhibit receptor activation or promote receptor endocytosis and lysosomal degradation 2 . The latter process is mediated by the formation of large protein complexes capable of removing activated receptors from the plasma membrane via clathrin-dependent and independent pathways [3] [4] [5] [6] . In this process, c-Cbl and Cbl-b proteins play a crucial role by acting as ubiquitin ligases as well as endocytic adaptor molecules. Cbl-mediated multiple monoubiquitination of RTKs sorts the receptor-containing vesicle to a degradation route and thereby leads to termination of the RTK signal [7] [8] [9] . Upon cell stimulation, Cbl proteins get translocated to activated RTKs and act as multifunctional adaptor proteins, capable of recruiting additional endocytic regulatory proteins such as CIN85-endophilin complexes, which facilitate receptor endocytosis.
A major function of CIN85 arises from its ability to bind to Cbl proteins as well as other effectors involved in regulation of receptor endocytosis [10] [11] [12] . Complex formation between CIN85 and Cbl occurs via the selective binding of SH3 domains of CIN85 to an atypical proline-arginine motif (PXXXPR, where X is any amino acid) present in the C-terminal region of c-Cbl and Cbl-b, and in other CIN85 effectors 13, 14 . Because CIN85 has three SH3 domains (SH3A, SH3B and SH3C; Fig. 1 ) that all recognize the same motif, it has been proposed that CIN85 acts as a platform for clustering of Cbl molecules, thereby contributing to efficient degradation of activated EGFRs 13 . The closest homolog of CIN85-SH3A (from now on referred to as CIN85A) outside of the CIN85/CMS protein family is b-PIX, which has 52% sequence identity (Fig. 1) . Notably, b-PIX has previously been shown to bind to a region of p21-activated kinase (Pak) that also contains an atypical proline-arginine motif 15 . Functionally, PIX proteins are believed to act as guanine nucleotide exchange factors (GEFs) for the small GTPases Rac and Cdc42 (refs. 15,16) , which regulate many cellular processes including cell polarity and motility, gene transcription and phagocytosis 17 . Recently, b-PIX/Cool-1 has been described as another Cbl-interacting protein that modulates EGFR downregulation 18 . It was shown that activated Cdc42-PIX complexes promote sequestration of Cbl from the EGFR and thereby block EGFR endocytosis 19 . The underlying mechanism has yet to be unraveled, but our recent findings imply that b-PIX binds to the proline-arginine motif in Cbl and thus may compete with CIN85 for binding to Cbl (data not shown).
SH3 domains are classic examples of protein interaction modules. They generally bind to proline-rich sequences containing a core PXXP motif, although other sequences may also be recognized [20] [21] [22] [23] . Many ligands bind their respective SH3 domains in a polyproline II helix (PPII) conformation 24 . Owing to the two-fold rotational pseudosymmetry of this conformation, peptides can bind a given SH3 domain in either one of two opposite directions governed by the location of a positively charged residue, usually arginine, which precedes or follows the core PXXP motif 25, 26 . SH3 domains associate with their ligands with a 1:1 stoichiometry, and proteins containing multiple SH3 domains can either serve as adaptor proteins to colocalize multiple proteins or bind multivalent ligands and thereby increase the affinity and specificity of a given interaction. An exception is the so-called 'SuperSH3' domain, first noted in the NADPH oxidase subunit p47 phox , in which two tandem SH3 domains cooperate to bind a single ligand 27 . This configuration seems to constitute a novel protein interaction module that provides greater flexibility for the recognition of multiple, diverse ligands.
To understand the functional role of complex formation between Cbl and CIN85 or b-PIX, we investigated these interactions in vitro and in vivo. Crystal structures of complexes between a Cbl-b peptide and SH3 domains of either human CIN85 or rat b-PIX reveal that, to our surprise, the Cbl peptide can interact simultaneously with two molecules of either SH3 domain. We demonstrate by isothermal titration calorimetry (ITC) that heterotrimerization also occurs in solution and is dependent on the presence of an N-terminal arginine in the Cbl-b peptide. Structural analysis of these complexes shows that they are distinct from those formed by SuperSH3 domains and explains why other targets of CIN85 or PIX do not support heterotrimerization. Finally we provide evidence that Cbl-induced binding to two CIN85 molecules also occurs in vivo, indicating a previously unknown role of Cbl in mediating formation of larger protein complexes involved in regulation of receptor endocytosis.
RESULTS

Overall structures of trimeric SH3-peptide complexes
Structures of complexes of CIN85A and the b-PIX SH3 domain each in complex with proline-arginine motif-containing peptides derived from Cbl-b were solved by molecular replacement and refined at resolutions of 2.0 and 1.85 Å , respectively. Each protein-peptide assembly crystallizes as a ternary complex that is composed of two SH3 domains and a single Cbl-b peptide (Fig. 2a,b (Fig. 2c,d ). Specific interactions via side chains are only made by Arg904 and Arg911 from Cbl-b at the extreme N and C termini of the peptide with Asp23 and Glu24 of each SH3 domain of PIX or Asp16 and Glu17 of CIN85A, respectively. Hydrophobic contacts are made by Pro906 and Pro910 from Cbl-b with conserved residues from each SH3 domain in both structures, whereas Pro908 is surrounded by hydrophobic residues from SH3B of the PIX or CIN85A complexes. Lys907 from the Cbl peptide plays a central role in both complexes. It is the only residue that makes simultaneous contacts with both SH3 domains through hydrogen bonds from its backbone carbonyl to the side chain amides of each, Asn58 in PIX-Cbl-b and Asn51 in CIN85A-Cbl-b. These contacts are pseudo-symmetrical and the backbone carbonyl of Lys907 constitutes the pseudo dyad axis of these interactions. Accordingly, equivalent interactions are established by Arg904 and Arg911 as well as Pro905 and Arg909 from Cbl-b (Fig. 2) . The pseudo-symmetry of interactions is slightly disrupted around Pro906, which makes a hydrogen bond analogous to that of Pro908 (to Tyr59 from PIX), while at the same time being in a similar hydrophobic environment as Pro910. The main difference between the PIX-Cbl-b and CIN85A-Cbl-b complexes is that the residue corresponding to Tyr59 in PIX is a phenylalanine in CIN85A and hence there is no hydrogen bond formed with the backbone carbonyls of Pro906 and Pro908.
Heterotrimeric complex formation in solution
The heterotrimeric CIN85A-Cbl-b and PIX-Cbl-b complexes described here are, to our knowledge, the first examples of peptideinduced dimerization of SH3 domains. To ensure that this is a general process that occurs in solution and is not solely an artifact of crystallization, we analyzed the SH3 domain-peptide interactions by ITC. Binding of the Cbl-b peptide to PIX-SH3 resulted in a curve that could be fit to a single-site binding model with an apparent dissociation constant of 14 mM and a stoichiometry of 1:0.57 ( Table 1 ), indicating that approximately only half the amount of peptide is required to form a complex with PIX. The same observation was made upon titration of CIN85A with the Cbl peptide: binding occurred with a stoichiometry of 1:0.57 and an apparent K d of 2.5 mM ( Table 1 and Fig. 3 ). In contrast, titration of PIX-SH3 with a peptide derived from Pak1 (ref. 15) resulted in formation of complexes with a stoichiometry of 1:0.95 and a K d of 3.2 mM ( Table 1) . Pak2 has been identified as a binding partner of CIN85 (ref. 14) . However, the affinity of the Pak1-derived peptide, which is highly homologous to Pak2, for CIN85A was rather weak (K d ¼ 68 mM), supporting the notion that CIN85B may be the preferred ligand for Pak 14 . Nevertheless, given the high protein and peptide concentrations used in this titration, the data could be fit reliably and showed a 1:1 stoichiometry ( Table 1 , data not shown).
Previous studies have indicated that Arg911 in Cbl-b (underlined in PXXXPR) is important for the interaction with CIN85 (refs. 13, 14) , an observation that can now be rationalized by the multiple hydrogen bonds formed between its guanidinium group and Asp16 and Glu17 from SH3B of CIN85A or Asp23 and Glu24 from SH3B of PIX, respectively. By contrast, Arg904, which makes equivalent contacts with SH3A from CIN85A and PIX, has not previously been implicated in complex formation. Our structures suggest that this residue may be crucial for peptide-induced dimerization, an idea supported by the observation that this arginine is absent in the Pak peptide, which binds either SH3 domain with a 1:1 stoichiometry. To test this hypothesis we measured binding of a mutant R904A Cbl peptide to CIN85A and PIX. Titration of CIN85A with this peptide clearly showed that stoichiometric amounts are required to saturate the SH3 domain with an affinity of 4.4 mM, further supporting our model ( Fig. 3 and Table 1 ). In contrast, mutation of Arg904 weakened the interaction with PIX to 140 mM, thereby making determination of the stoichiometry of the interaction somewhat unreliable. Nevertheless, considerably more than half an equivalent of mutant peptide is required to approach saturation, suggesting that this interaction also occurs with a 1:1 stoichiometry. All titrations apart from CIN85A with Pak and b-PIX SH3 with mutant Cbl-b were carried out between two and four times and the estimated error is the s.d. between measurements. The latter two titrations were carried out only once owing to the high protein and peptide concentrations required for these weak interactions. The error given for these titrations is the error of the respective fit. The optimal fits for these two titrations give a K d of 1.7 mM and an n of 0.61 for the wild-type peptide and a K d of 3.6 mM and an n of 1.27 for the mutant R904A peptide. To better illustrate the different stoichiometries between these two titrations the x-axes are shown on the same scale. The dissociation constant determined for the CIN85A-Cbl-b complex is only an apparent K d as it includes binding as well as trimerization.
The stoichiometry of the CIN85A-Cbl-b complex described in this manuscript differs from an earlier study, which reported a 1:1 complex 13 . At present we are not certain about the reasons for this discrepancy but believe that it is probably due to the experimental conditions and the size of the constructs used, which differ extensively between the two studies.
In vivo interactions between c-Cbl/Cbl-b and CIN85 Previous findings have indicated that the C-terminal leucine zipper (LZ) of c-Cbl mediates protein dimerization and thereby formation of larger complexes needed for efficient EGF-receptor downregulation 28 . The data presented here suggest that Cbl proteins may additionally contribute to the formation of such complexes by simultaneously interacting with two CIN85-SH3 domains. We first tested whether c-Cbl that also contains the pseudo-symmetrical proline-arginine motif can promote ternary complex formation with CIN85 in vivo by cotransfection of full-length CIN85 and Flag-CIN85-3SH3 with different c-Cbl mutants in HEK293T cells. Flag-CIN85-3SH3 (a construct containing the three SH3 domains of CIN85) is impaired in its ability to oligomerize because it lacks the coiled-coil motif and hence cannot form heterocomplexes with wild-type CIN85 (ref. 13 ). This makes it particularly useful in monitoring interactions between SH3 domains of CIN85 in the presence or absence of a potential linker such as c-Cbl. Accordingly, coprecipitation between CIN85 and Flag-CIN85-3SH3 was detected at very low levels in cells, probably owing to the presence of endogenous c-Cbl (Fig. 4a) . By contrast, coprecipitation was increased upon coexpression with a c-Cbl deletion mutant lacking the LZ domain (c-Cbl-849), which retained its ability to bind to Flag-CIN85-3SH3 (Fig. 4a, top panel) . This mutant was used to ensure that coprecipitation was a consequence of binding of two independent CIN85 molecules to a single c-Cbl molecule rather than of the interaction with homodimeric c-Cbl 28 . More importantly, a c-Cbl mutant (c-Cbl-827) lacking the LZ domain and the prolinearginine binding site did not interact with SH3 domains of CIN85 and thus did not promote coprecipitation between Flag-CIN85-3SH3 and wild-type CIN85 (Fig. 4a, bottom panel) . Because the crystal structures and ITC studies presented here indicate that Arg904 in the Cbl-b peptide is crucial for allowing its heterotrimerization with CIN85-SH3A, we analyzed the role of this residue on the in vivo interaction between CIN85 and Cbl-b (Fig. 4b) . A Cbl-b deletion mutant lacking the LZ/UBA domain (Cbl-b-927), which cannot homodimerize, interacted strongly with SH3 domains of CIN85, whereas Cbl-b-927 R904A was reduced, but not blocked, in its ability to coprecipitate with Flag-CIN85-3SH3 (Fig. 4b) . Furthermore, the Cbl-b-927 R904A mutant was impaired in its ability to mediate formation of a complex between full-length CIN85 and Flag-CIN85-3SH3 (Fig. 4b) . We noticed that c-Cbl was consistently more effective than Cbl-b in inducing trimerization with CIN85 (Fig. 4a,b) . However, the pseudo-symmetrical proline-arginine motif is almost identical in both Cbl isoforms, indicating that this effect must be caused by differences in other regions of the two proteins. Because of its stronger binding, we used c-Cbl to quantify the relative contributions of the two conserved arginines, Arg822 and Arg829, to interaction with and trimerization of CIN85. Mutation of either Arg822 or Arg829 considerably reduced their ability to promote simultaneous binding to full-length CIN85 and Flag-CIN85-3SH3 (Fig. 4c) , supporting the conclusion that an intact pseudosymmetrical proline-arginine motif is required to allow Cbl proteins to promote formation of the heterotrimeric complex in vivo. However, heterotrimerization was not completely abolished, suggesting that, in cells, either additional interacting partners of c-Cbl and CIN85 may indirectly contribute to formation of the heterologous complex or regions outside the core binding motif may further stabilize this complex.
To determine the functional role of the individual arginines in fulllength c-Cbl and Cbl-b in binding to CIN85 and receptor downregulation, we separately mutated either Arg822 or Arg829 in c-Cbl, or Arg904 or Arg911 in Cbl-b; additionally, we mutated both of them simultaneously. The amount of CIN85 coprecipitated with c-Cbl and Cbl-b proteins was quantified and showed that mutation of Arg829 and Arg911 reduced the interaction with CIN85 by approximately 80 and 60%, respectively, whereas mutation of Arg822 or Arg904 reduced binding by B25%. Mutation of both sites in either c-Cbl or Cbl-b largely abolished their coprecipitation with CIN85 (Fig. 4d) . Last, we tested the functional importance of these arginines by measuring the downregulation rate of EGF receptors in cells transfected with different Cbl mutants. Expression of dimerization-deficient c-Cbl-849 or Cbl-b-927 in HEK293 cells enhanced EGF-induced degradation of EGF receptors (Fig. 4e,f) . This effect was substantially reduced when either of the two arginine residues was mutated, indicating that both play important roles in pathways controlling EGF-receptor downregulation. These findings, together with our data on heterotrimerization of CIN85 by c-Cbl and Cbl-b (Fig. 4a-c) , point to an important and previously unaccounted role of Cbl-b Arg904 and c-Cbl Arg822 in Cbl-mediated clustering of CIN85 and controlling endocytic trafficking of EGF receptors.
DISCUSSION
It has become evident that the interaction of c-Cbl or Cbl-b with adaptor proteins such as CIN85 and PIX is an important mechanism to modulate and fine-tune RTK endocytosis and degradation 2 . The same proline-arginine motif in the C-terminal portion of c-Cbl or Cbl-b is recognized by SH3 domains present in both proteins, suggesting that they may act in a competitive fashion with respect to Cbl. We report here the crystal structures of complexes between a Cbl-b proline-arginine peptide and the SH3 domains of b-PIX and CIN85 (SH3A), respectively. Notably, the Cbl peptide induces formation of a heterotrimeric complex consisting of two SH3 domains and one peptide molecule in both structures. Interactions made by the Cbl peptide with b-PIX and CIN85A are very similar and the peptide binds simultaneously in class I and II orientations. Key to this unusual arrangement is the pseudo-symmetry of the peptide sequence, which allows two arginines, Arg904 and Arg911, to make equivalent hydrogen bonds with acidic residues in each SH3 domain. This pseudosymmetry is also preserved in c-Cbl owing to the presence of Arg822 and Arg829. The previously shown requirement of Arg911 for complex formation can now be rationalized by the extensive interactions between this residue and the SH3 domain: the guanidinium side chain is involved in a network of hydrogen bonds with acidic residues in the RT loop while its aliphatic portion stacks against Trp43 in PIX and Trp36 in CIN85. Arg904, by contrast, has not been previously recognized as important for complex formation with CIN85. Its presence seems to define the multimerization state of the SH3-peptide complexes and hence indicates why other ligands that also contain the PXXXPR motif, but lack the N-terminal arginine, such as Pak, bind with a 1:1 stoichiometry. Furthermore, it suggests that other targets of CIN85 that lack the N-terminal arginine such as BLNK or CD2 should bind in a 1:1 fashion. Notably, mutation of this arginine does not appreciably change the apparent affinity of the peptide for CIN85A, but changes the relative enthalpic and entropic contributions to DG. In contrast, binding to PIX-SH3 is weakened ten-fold upon mutation of Arg904, indicating that despite the similarity between the two structures there must be differences in the mechanism of complex formation. Notably, in vivo, neither mutation of Arg822 nor that of Arg829 (the equivalent residues in c-Cbl) completely abolishes heterotrimerization. This may indicate that in the context of the full-length proteins, residues outside of the core motif might contribute to the stabilization of a heterotrimeric complex, or alternatively that additional interacting proteins may indirectly contribute to their coprecipitation by forming multimeric complexes.
Comparison with SuperSH3 domains
The PIX-Cbl and CIN85-Cbl structures are at present the only examples of ternary SH3 domain-peptide complexes in which the peptide induces dimerization and potentially oligomerization of its targets. The only other example of SH3-ligand complexes in which the ligand is shared between two SH3 domains is p47 phox in the autoinhibited and the p22 phox -bound state, a structural arrangement that has been termed the SuperSH3 domain 27 . However, in contrast to the structures described here, the SH3 domains of p47 phox are covalently linked and this link is required to allow the two SH3 domains to simultaneously bind the same peptide. Although the individual SH3 domains of the p47 phox and PIX or CIN85 structures overlap well with one another, an overlap of the trimeric PIX-Cbl structure with that of the dimeric p47-p22 phox complex shows that the second SH3 domain in each structure occupies a different position (Fig. 5) . In the PIXCbl-b and CIN85A-Cbl-b complexes, the two SH3 domains come closest at Asn58 of PIX and Asn51 of CIN85, situated in a 3 10 -helix in the C-terminal portion of the proteins (Figs. 1 and 2) . In p47 phox , the n-Src loops come closest, burying 579 Å 2 of solvent-accessible surface (through direct domain interactions) and contributing to the stability of the SuperSH3 domain conformation through hydrogen bonds across the interface. A GWW motif present in each n-Src loop acts as a signature motif of SuperSH3 domains 27 . The glycine is required for steric complementarity while the second tryptophan residue makes important interactions across the interface. Notably, PIX as well as all three SH3 domains of CIN85 contain this motif (Fig. 1) . Nevertheless, their relative orientation in the heterotrimeric structures described here is different from that observed in p47 phox and residues of the n-Src loop do not contribute to trimerization. This suggests that the new structures presented here are not additional examples of SuperSH3 domains but rather constitute a novel mechanism by which SH3 domains can contribute to the formation of multiprotein complexes.
Cbl-mediated protein multimerization in endocytosis Efficient receptor endocytosis requires the formation of large protein complexes surrounding activated receptors 4, 29 . In many instances, specialized endocytic scaffold proteins engage multiple effectors and couple trafficking cargo with the clathrin coat, actin cytoskeleton and endocytic vesicles. Among them are Cbl proteins that interact with a CIN85-endophilin complex and control receptor internalization 4 . Previously it has been shown that CIN85 contributes to receptor internalization by clustering Cbl proteins via its three SH3 domains 13 . However, the findings presented here reveal yet another mechanism by which Cbl proteins can contribute to the formation of signalcompetent complexes implicated in receptor endocytosis. Biochemical studies in cells clearly indicate that the proline-arginine motif in Cbl can simultaneously accommodate two SH3 domains from separate CIN85 molecules (Fig. 4) and could thereby promote the formation of higher-order Cbl-CIN85 complexes. At present we cannot exclude that adjacent SH3 domains in CIN85 may act in a similar manner and cooperate to bind a single ligand. Further studies are required to understand such a potential interplay between SH3A, SH3B and SH3C in the context of the full-length protein. Nevertheless, consistent with our findings, complexes of high molecular mass containing Cbl and CIN85 have been found in cellular lysates 30 . Furthermore, the identification of Arg904 in Cbl-b as an additional binding surface for SH3 domains explains how Cbl-mediated multimerization of CIN85 proteins occurs in vivo. The physiological importance of these Cbl functions is likely to be relevant in the assembly of multiprotein complexes during receptor downregulation 13, 28, 31 . Notably, the b-PIX-SH3 domain binds in the same manner to Cbl proteins as CIN85. Thus, the competition of b-PIX and CIN85 for binding to the same surface of Cbl may represent the basis for dissociation of Cbl away from the activated EGF receptor upon activation of Cdc42-PIX complexes 19 .
Taken together, we have identified crucial residues in the prolinearginine motif of c-Cbl and Cbl-b involved in formation of a ternary complex with the adaptor proteins CIN85 and b-PIX and the assembly of the endocytic machinery that governs downregulation of activated receptor tyrosine kinases. Future research should now be directed toward the visualization and dynamics of the formation of Cbl-linked protein complexes in cells and their live imaging during receptor trafficking in the endosome.
METHODS
Protein overexpression and purification. For CIN85A, the N-terminal SH3 domain of human CIN85 (residues 1-58) was cloned into pET29b and overexpressed in Escherichia coli strain Rosetta(DE3)pLysS at 30 1C. Cell lysates were precipitated with 50% (w/v) ammonium sulfate, the precipitate was discarded by centrifugation at 35,000g for 15 min and more ammonium sulfate was added to the supernatant to 70% saturation. After centrifugation, the CIN85A-containing supernatant was adjusted to 50% (w/v) ammonium sulfate, loaded onto a 5-ml HiTrap Phenyl FF (high sub) hydrophobic interaction column (Amersham Biosciences) and eluted with a linear ammonium sulfate gradient (50% to 0%). CIN85A-containing fractions were pooled, concentrated and loaded onto a HiLoad 16/60 Superdex 75 gel filtration column equilibrated with buffer B (20 mM Tris (pH 7.5) and 150 mM NaCl).
For b-PIX-SH3, the SH3 domain of rat b-PIX (residues 5-66) 15 was cloned into pGEX-4T1 and expressed in E. coli strain BL21 at 30 1C. The protein was purified on glutathione Sepharose 4B (Amersham Biosciences) and cleaved oncolumn with human a-thrombin protease (HTI). Further purification was carried out by gel filtration on Superdex 75 (Amersham Biosciences) in 20 mM Tris (pH 7.5) and 50 mM NaCl. The purified domain was concentrated in VivaSpin concentrators (VivaScience) to B1 mM and stored at -70 1C after shock freezing in liquid nitrogen.
Isothermal titration calorimetry. Complex formation between the SH3 domains of PIX and CIN85 and various peptides was measured by ITC using a MicroCal VP-ITC microcalorimeter (MicroCal) 32 . The peptides used were Cbl-b, SQAPARPPKPRPRRTAY (the C-terminal tyrosine was introduced to allow spectrophotometric determination of the peptide concentration); and Pak, DATPPPVIAPRPEHTKSVYTR. A NAP 5 column was used to exchange all proteins into ITC buffer (50 mM Tris or HEPES (pH 7.5) and 50 mM NaCl). Experiments were done at 18 1C. In general the sample cell contained either SH3 domain at concentrations of 20-200 mM and peptide solutions at approximately ten times the protein concentration in the cell were injected in 10-ml samples from a total of 290 ml. Heats of dilution, determined by titrating the peptides into buffer alone, were subtracted from the raw titration data before analysis. Data were fitted by least-squares procedures assuming a one-site binding model using Microcal Origin version 7.0 (Microcal). All measurements were repeated two to four times (apart from those mentioned in the figure legend).
Crystallization, data collection, structure determination and refinement. Table 2 ). The structure was solved by molecular replacement using the MOLREP 34 with PDB entry 1SEM 26 as a search model. An automatic water search and refinement was done with ARP/REFMAC 35, 36 showing clearly the position of Cbl-b. The model of the complex was built in MAIN 37 followed by cycles of refinement in REFMAC 36 . The data were refined to a resolution of 1.85 Å containing residues 6-65 and 3-66 of b-PIX and 904-911 of Cbl-b. The stereochemical quality of the protein model was constantly monitored during the course of refinement with PROCHECK 38 . The protein model is of excellent stereochemical quality, with all residues lying in the preferred F and C regions. The Cbl-b peptide (PARPPKPRPRR, Sigma Genosys) was added to CIN85A at a 1:2.5 protein/peptide ratio and 6.96 mM (47.1 mg ml -1 ) final concentration in 20 mM Tris-HCl (pH 7.5) and 150 mM NaCl). Crystals were obtained by hanging drop vapor diffusion by mixing 0.5 ml of protein solution with 0.5 ml of reservoir solution (0.8 M Na citrate, 0.1 M Bis-Tris (pH 7.5) and 0.2 M NaCl). For cryoprotection 10% (v/v) ethylene glycol was added. A 2.0 Å -resolution data set was collected at 100 K on a rotating anode ( Table 2) . Diffraction data were reduced using the HKL package, DENZO and SCALEPACK 33 . Crystals of CIN85A-Cbl-b belong to space group P6 5 . A twinning fraction between 25% and 31% was detected. Initial phases for CIN85A-Cbl-b were calculated from a single AmoRe 39 molecular replacement solution with a correlation coefficient of 24.1 and an R-factor of 47.6% by using a previously solved isolated CIN85A structure as a search model (N.C. and J.B., unpublished data). The final model was obtained by combining cycles of automatic refinement in CNS 40 (considering a twinning fraction of 0.305 for the operator k, h, l) and manual model building using COOT 41 or Xtalview/Xfit 42 . Residue 58 in molecule SH3A of CIN85A is disordered. A total of 82 water molecules have been added to the final model. PROCHECK 38 indicates that 99% of the residues are in the allowed regions of F and C conformational space.
Biochemical assays and EGF-receptor degradation assay. Cell transfection with indicated cDNAs, cell lysis, immunoprecipitation and immunoblotting were done as previously described 13 . The CIN85 antibody is a rabbit polyclonal antibody directed against the C terminus of CIN85 and hence does not recognize the Flag-CIN85-3SH3 construct. Immunoblots were quantified using NIH ImageJ 43 . Degradation assays were done as previously described 30 . Point mutations in c-Cbl and Cbl-b were introduced using a modified Stratagene QuikChange mutagenesis protocol and verified by DNA sequencing. 293T cells were transfected with EGFR-GFP and either Cbl-b-927, Cbl-b-927 R904A, Cbl-b-927 R911A or empty vector (control) in 10-cm cell culture dishes. After 24 h, cells were split into 12-well dishes and starved overnight in serum-free medium. The next day cells were left unstimulated or were incubated with EGF (50 ng ml -1 ) for 60 or 120 min at 37 1C. Cells were harvested after stimulation and analyzed using the Epics XL flow cytometer (Beckman Coulter). For each sample, 10,000 GFP-positive cells were gated and the intensity of green fluorescence determined. Equal expression of the transfected proteins was checked by immunoblotting. 
